Front Cover: Discovery of 1,3,4-Oxadiazin-5-One Derivative CJ1-34 as a Partial ATP Synthase Inhibitor for CNS Applications

Abstract

The lead compound CJ1-34 (orange), derived from 1,3,4-oxadiazin-5-one, targets the F1 region of ATP synthase (purple). This binding site is located within the mitochondrial matrix, as shown by a cross-section of a mitochondrion. A close-up of the F1 region highlights the proposed binding site of CJ1-34 based on docking studies. Together with the physiochemical properties, these findings indicate CJ1-34'S potential as a drug for diseases of the central nervous system. More information can be found in the Research Article by L. Mu and co-workers (DOI: 10.1002/chem.202404517).